消化管 angiodysplasia の薬物療法
Rita Tinoco Magalhães1, Rita Valadas1, Patrícia Cipriano1
1Internal Medicine Department, Hospital de Cascais Dr. José de Almeida, Portugal.
まとめ
消化管 angiodysplasia (GIAD)の薬物療法は有望であり、オクトレオチドは有効性と最小限の副作用を示しています。不明瞭な消化管出血の臨床診療を導くためには、サリドマイドとこれらを比較した研究に関するさらなる研究が必要です。
科学分野:
- 消化器病学
- 薬理学
背景:
- 消化管 angiodysplasia (GIAD)は、不明瞭な消化管出血の頻繁な原因です。
- 薬理学的介入は、内視鏡治療に反応しないGIADまたは外科的に困難な部位の症例にとって重要です。
研究 の 目的:
- GIADの薬理学的管理戦略をレビューおよび分析すること。
- GIAD治療におけるホルモン療法、サリドマイド、およびオクトレオチドの有効性と安全性を評価すること。
主な方法:
- 関連研究を特定するために包括的な文献検索を実施しました。
- 含まれた研究は、ホルモン療法、サリドマイド、およびオクトレオチドに焦点を当てたGIADの薬理学的治療に焦点を当てました。
- 325件の参考文献をスクリーニングした後、59件の出版物からのデータを分析しました。
主要な成果:
- ホルモン療法は、一貫性のない有効性と注目すべき副作用を示しました。
- サリドマイドは潜在的な利点を示しましたが、重大な有害事象を伴いました。
- オクトレオチドは、特にその徐放性製剤において、有効性と良好な安全性プロファイルを示しました。
結論:
- オクトレオチドとサリドマイドは、GIADの有望な治療選択肢を表しています。
- これらの薬剤の有効性と安全性を完全に評価し、臨床的意思決定に情報を提供するためには、比較研究を含むさらなる研究が不可欠です。
関連する概念動画
Peptic Ulcer Disease IV: Management
439
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
439
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
Drugs for Treatment of Diarrhea-Predominant IBS
635
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
635
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
465
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
465
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
900
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
900


